LMR Partners’s Xenon Pharmaceuticals XENE Stock Holding History

LMR Partners’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-98,600	Closed	-$4.54M	–	1335
2023 Q4	$4.54M	Buy	+98,600	New	+$3.48M	0.05%	329

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

LMR Partners's XENE Position: Q2 2026 in Review

LMR Partners sold out of Xenon Pharmaceuticals (XENE) in Q2 2026, closing a stake of 56,200 shares — an estimated $3.27M sold.

LMR Partners first reported a position in XENE in Q2 2022 and held it in 10 quarters. The position peaked at $3.27M in Q1 2026. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

LMR Partners reported no remaining Xenon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
LMR Partners sold 56,200 Xenon Pharmaceuticals shares in Q2 2026, an estimated $3.27M.
LMR Partners first reported a position in Xenon Pharmaceuticals in Q2 2022 and held it in 10 quarters.
LMR Partners's Xenon Pharmaceuticals position peaked at $3.27M in Q1 2026.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on LMR Partners's 13F filing for Q2 2026, filed 14 Aug 2026.